2019
DOI: 10.1016/j.jim.2019.112641
|View full text |Cite
|
Sign up to set email alerts
|

Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 51 publications
0
8
0
Order By: Relevance
“…In symptomatic visceral leishmaniasis, there is an increased antibody response, both in dogs and in humans, and recombinant antigen-based assays can thus be used [33][34][35]. The challenge is asymptomatic leishmaniasis, in which we face a low serology against the protozoan, the tests showing a reduced sensitivity, as well as a cross-reactivity with other pathologies such as tuberculosis, Chagas disease, or malaria, which reduces the tests' specificity [36,37]. Recently, the rLiHyQ protein was identified in the antigens of the protozoan leishmania; this was cloned and used in ELISA experiments for determining the diagnosis in both human and canine leishmaniasis, showing sensitivity and specificity even in HIV-coinfected patients [19].…”
Section: Diagnosis In Humans Leishmaniasismentioning
confidence: 99%
“…In symptomatic visceral leishmaniasis, there is an increased antibody response, both in dogs and in humans, and recombinant antigen-based assays can thus be used [33][34][35]. The challenge is asymptomatic leishmaniasis, in which we face a low serology against the protozoan, the tests showing a reduced sensitivity, as well as a cross-reactivity with other pathologies such as tuberculosis, Chagas disease, or malaria, which reduces the tests' specificity [36,37]. Recently, the rLiHyQ protein was identified in the antigens of the protozoan leishmania; this was cloned and used in ELISA experiments for determining the diagnosis in both human and canine leishmaniasis, showing sensitivity and specificity even in HIV-coinfected patients [19].…”
Section: Diagnosis In Humans Leishmaniasismentioning
confidence: 99%
“…In symptomatic visceral leishmaniasis, there is an increased antibody response, both in dogs and in humans, and recombinant antigen-based assays can thus be used ( Dhom-Lemos et al., 2019 ; Lévêque et al., 2020 ; Pereira et al., 2020 ). The challenge is asymptomatic leishmaniasis, in which we face a low serology against the protozoan, the tests showing a reduced sensitivity, as well as a cross-reactivity with other pathologies such as tuberculosis, Chagas disease, or malaria, which reduces the tests’ specificity ( Daltro et al., 2019 ; Rodrigues et al., 2019 ). Recently, the rLiHyQ protein was identified in the antigens of Leishmania spp.…”
Section: Diagnosis In Human Leishmaniasismentioning
confidence: 99%
“…Other recombinant proteins, such as cytochrome c oxidase, putative IgE histamine releasing factor, prohibitin, eukaryotic initiation factor 5a, cathepsin L-like peptide and small myristoylated protein-3, as well as hypothetical proteins, were evaluated in preliminary studies demonstrating potential as candidates for TL-immunodiagnosis, and so more studies are desirable [27,29,30,93]. Some promising synthetic peptides have been identified and employed in ELISA.…”
Section: Plos Onementioning
confidence: 99%